The modest revenue growth and expanding losses may pressure sentiment, but the clinical milestones ahead in 2026–2027—especially IND filings and potential BLA submission for PM359—could serve as key catalysts. Traders should monitor FDA feedback on PM359 and preclinical updates for CF and liver programs.
Price Chart
Executive Summary
Prime Medicine reported its full-year 2025 financial results and provided a business update, highlighting progress in its Prime Editing pipeline, including plans to file IND/CTA for Wilson Disease and AATD programs in 2026, with initial clinical data expected in 2027. The company also noted ongoing FDA engagement for PM359 in CGD, supported by published Phase 1/2 data, and maintained a cash runway into 2027 with $191.4 million in cash and investments.
Key Financial Metrics
Key Facts
- R&D expenses increased to $160.6 million in 2025 from $155.3 million in 2024.
- G&A expenses rose to $52.3 million in 2025 from $50.2 million in 2024.
- Net loss widened to $201.1 million in 2025 from $195.9 million in 2024.
- Cash, cash equivalents, investments, and restricted cash totaled $191.4 million as of December 31, 2025, down from $204.5 million in 2024.
- Company expects cash runway into 2027.
- Plans to submit IND/CTA for Wilson Disease in 1H 2026 and AATD in mid-2026; initial clinical data expected in 2027.
- PM359 for CGD showed positive Phase 1/2 data published in NEJM; company plans BLA submission following FDA alignment.
Financial Impact
Revenue increased to $4.6 million in 2025 from $3.0 million in 2024, but net loss expanded to $201.1 million. Cash position decreased by $13.1 million year-over-year.
Risk Factors
- Continued net losses and cash burn could lead to future dilution.
- Regulatory delays in IND/CTA filings or BLA submission for PM359.
- Preclinical and clinical data may not replicate prior success, especially in new indications.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248274 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | Press Release | $2.90 | awaiting T+60 | — | $4.13 (+42.24%) |
Aug 6, 2026 11w ago | 8-K | $2.95 | awaiting T+60 | — | $4.13 (+39.83%) |
Jul 8, 2026 15w ago | 8-K | $4.62 $3.06 | ▼ −33.87% | ▼ −36.19% | $4.13 (−10.71%) |
Jun 18, 2026 18w ago | Press Release | $3.23 $3.18 | ▼ −1.55% | ▼ −3.44% | $4.13 (+27.71%) |
May 7, 2026 24w ago | 8-K | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $4.13 (−32.42%) |
May 7, 2026 24w ago | Press Release | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $4.13 (−32.42%) |
Apr 16, 2026 27w ago | 8-K | $3.67 $3.52 | ▼ −4.22% | ▼ −11.27% | $4.13 (+12.40%) |
Mar 3, 2026 34w ago | Press Release | $4.23 $3.30 | ▼ −21.99% | ▼ −32.30% | $4.13 (−2.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers